It’s been almost a year since the Food and Drug Administration approved the first genetic treatments for sickle cell disease.

Analysts at Precedence Research expect the gene-editing market to grow 15.7% annually and reach $29.9 billion by 2032, ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

The severity of these rarer types of sickle cell disease varies. — Hemoglobin S–beta-thalassemia: When individuals are diagnosed with this form of sickle cell disease, they inherit one sickle cell ...

The first therapy that uses gene-editing is to be offered on the NHS in a “revolutionary breakthrough” for patients. It will ...

He also believes there’s still too few of the therapies on the market to draw any sweeping conclusions on reasons for their ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group (LSEG). Any PEG ratio below 1.0 is viewed as an attractive valuation.

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare ...

For those with $200 to spare that isn't being saved for emergencies, let's consider two healthcare stocks within that budget ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $508.38, a high estimate of ...

Fintel reports that on September 9, 2024, B of A Securities upgraded their outlook for Fulcrum Therapeutics (NasdaqGM:FULC) ...

LEXINGTON, Ky. (WKYT) - WKYT’s blood drive kicks off tomorrow! You’ll be able to give blood at five locations in Central ...